FDA Accepted Application for Inhaled IPF Treatment
The regulatory body is reviewing an inhaled option that could change how patients with idiopathic pulmonary fibrosis manage lung function.
Updated on Sept. 30, 2026 in Asthma
Live Poll
Do you trust that new specialty medical treatments will be affordable for your household?
On September 2, 2026, the FDA accepted a supplemental new drug application for inhaled treprostinil to treat idiopathic pulmonary fibrosis (IPF). If approved, this would mark the first inhaled antifibrotic treatment available to the estimated 100,000 Americans living with the condition.
Why it matters
Currently, IPF patients rely on oral therapies like nintedanib and pirfenidone; an inhaled option would offer an alternative delivery method for those managing this progressive lung disease. Because the disease requires long-term care, understanding the landscape of potential treatments and their delivery systems is essential for patients.
In the TETON-1 and TETON-2 Phase 3 clinical trials, participants using inhaled treprostinil showed a 111.8 mL improvement in forced vital capacity compared to those on a placebo over 52 weeks. These results compare the new inhaled approach against a control group to measure lung function preservation.
The players
United Therapeutics
A biotechnology company that develops treatments for pulmonary arterial hypertension and other lung diseases.
Food and Drug Administration
The federal regulatory agency responsible for evaluating the safety and efficacy of medical treatments in the United States.
The details
Inhaled treprostinil is administered directly into the lungs using durable medical equipment to provide antifibrotic support. This targeted delivery is intended to help stabilize lung function in patients with idiopathic pulmonary fibrosis by slowing the progression of scarring in the lung tissue. The therapy is already approved for other conditions, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Timeline
September 2, 2026: The FDA officially accepted the supplemental new drug application.
May 2026: Combined trial results were presented at the American Thoracic Society conference.
Late April 2027: The FDA review of the application is expected to be completed.
Health Landscape
This application marks a potential shift in the therapeutic landscape for IPF, which currently relies on oral antifibrotic medications. The submission builds on the results of the TETON-1 and TETON-2 phase 3 clinical trials, which aimed to improve upon current standard-of-care options.
If you are managing idiopathic pulmonary fibrosis, discuss the implications of emerging delivery methods with your physician to understand how they might compare to your current oral regimen. Be aware that insurance coverage for new treatments involving durable medical equipment may vary, so check with your provider regarding potential costs.
The takeaway
The potential approval of an inhaled antifibrotic represents a new delivery option for managing pulmonary fibrosis. Patients should continue monitoring their lung function and discuss with their pulmonologist whether they might be candidates for future, non-oral treatment developments.
What happens next
The FDA is expected to complete its review of the drug application in late April 2027, which will determine if the treatment receives approval.
Further reading
Learn more about the latest developments in respiratory care at United States Asthma.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that new specialty medical treatments will be affordable for your household?
